©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2022; 10(36): 13467-13469
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13467
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13467
Precautions before starting tofacitinib in persons with rheumatoid arthritis
Raktim Swarnakar, Shiv Lal Yadav, Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, New Delhi, New Delhi 11049, Delhi, India
Author contributions: Swarnakar R and Yadav SL contributed to conception and design; Swarnakar R and Yadav SL contributed to literature search and writing.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Raktim Swarnakar, MBBS, MD, Doctor, Department of Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, New Delhi, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, New Delhi 11049, Delhi, India. raktimswarnakar@hotmail.com
Received: September 14, 2022
Peer-review started: September 14, 2022
First decision: October 13, 2022
Revised: October 30, 2022
Accepted: December 5, 2022
Article in press: December 5, 2022
Published online: December 26, 2022
Processing time: 102 Days and 23.6 Hours
Peer-review started: September 14, 2022
First decision: October 13, 2022
Revised: October 30, 2022
Accepted: December 5, 2022
Article in press: December 5, 2022
Published online: December 26, 2022
Processing time: 102 Days and 23.6 Hours
Core Tip
Core Tip: Tofacitinib is a disease-modifying drug in rheumatoid arthritis. It has many side effects, especially in susceptible people. Before starting tofacitinib we must take precautions regarding cardiovascular status, infections and malignancy.